IONS Ionis Pharmaceuticals Inc

Price (delayed)

$48

Market cap

$7.01B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.67

Enterprise value

$8.1B

Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and ...

Highlights
The gross profit is up by 36% year-on-year
IONS's revenue is up by 35% YoY
IONS's quick ratio is down by 26% year-on-year but it is up by 25% since the previous quarter
The company's equity fell by 39% YoY and by 23% QoQ
The net income has declined by 17% year-on-year and by 5% since the previous quarter

Key stats

What are the main financial stats of IONS
Market
Shares outstanding
145.97M
Market cap
$7.01B
Enterprise value
$8.1B
Valuations
Price to book (P/B)
23.59
Price to sales (P/S)
9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.43
Earnings
Revenue
$776.62M
EBIT
-$277.31M
EBITDA
-$254.76M
Free cash flow
-$341.26M
Per share
EPS
-$2.67
Free cash flow per share
-$2.34
Book value per share
$2.03
Revenue per share
$5.34
TBVPS
$18.99
Balance sheet
Total assets
$2.76B
Total liabilities
$2.47B
Debt
$1.44B
Equity
$296.52M
Working capital
$2.09B
Liquidity
Debt to equity
4.87
Current ratio
7.37
Quick ratio
6.75
Net debt/EBITDA
-4.3
Margins
EBITDA margin
-32.8%
Gross margin
98.7%
Net margin
-49.5%
Operating margin
-50.1%
Efficiency
Return on assets
-13.2%
Return on equity
-107.9%
Return on invested capital
-7.7%
Return on capital employed
-11.4%
Return on sales
-35.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IONS stock price

How has the Ionis Pharmaceuticals stock price performed over time
Intraday
1.46%
1 week
4.14%
1 month
15.66%
1 year
12.89%
YTD
-5.12%
QTD
0.71%

Financial performance

How have Ionis Pharmaceuticals's revenue and profit performed over time
Revenue
$776.62M
Gross profit
$766.68M
Operating income
-$389.1M
Net income
-$384.77M
Gross margin
98.7%
Net margin
-49.5%
The operating margin is up by 38% year-on-year but it has declined by 12% since the previous quarter
The gross profit is up by 36% year-on-year
IONS's revenue is up by 35% YoY
The net income has declined by 17% year-on-year and by 5% since the previous quarter

Growth

What is Ionis Pharmaceuticals's growth rate over time

Valuation

What is Ionis Pharmaceuticals stock price valuation
P/E
N/A
P/B
23.59
P/S
9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.43
Ionis Pharmaceuticals's EPS has decreased by 16% YoY and by 4.3% QoQ
The stock's price to book (P/B) is 134% more than its 5-year quarterly average of 10.1 and 27% more than its last 4 quarters average of 18.6
The company's equity fell by 39% YoY and by 23% QoQ
IONS's revenue is up by 35% YoY
The P/S is 10% more than the 5-year quarterly average of 8.2 but 3.2% less than the last 4 quarters average of 9.3

Efficiency

How efficient is Ionis Pharmaceuticals business performance
IONS's return on equity has dropped by 87% year-on-year and by 19% since the previous quarter
Ionis Pharmaceuticals's return on sales has increased by 28% YoY but it has decreased by 11% QoQ
Ionis Pharmaceuticals's ROIC has increased by 13% YoY but it has decreased by 12% from the previous quarter
IONS's return on assets is down by 6% since the previous quarter and by 3.1% year-on-year

Dividends

What is IONS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IONS.

Financial health

How did Ionis Pharmaceuticals financials performed over time
The total assets is 12% greater than the total liabilities
IONS's quick ratio is down by 26% year-on-year but it is up by 25% since the previous quarter
The current ratio rose by 25% since the previous quarter but it has declined by 25% year-on-year
Ionis Pharmaceuticals's debt to equity has soared by 74% YoY and by 30% from the previous quarter
The company's equity fell by 39% YoY and by 23% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.